Anika Therapeutics | ANIK - Ebitda


Anika Therapeutics reported $4.54M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
Agenus USD -10.11M 19.02M Mar/2025
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -148.3M 165.88M Mar/2026
Integra LifeSciences USD 78.41M 2.23M Jun/2026
Intrexon USD -24.7M 2.92M Jun/2024
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD -14.3M 81.08M Mar/2026
MacroGenics USD -30.2M 52.15M Mar/2026
Merit Medical Systems USD 104.39M 10.97M Jun/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Sanofi EUR 3.69B 375M Jun/2026
Smith & Nephew USD 796M 139M Dec/2025
Stryker USD 1.93B 357M Jun/2026
Veracyte USD 43.96M 1.16M Jun/2026
Xencor USD -34.63M 86.74M Jun/2026
Zimmer Biomet Holdings USD 830.5M 190.4M Jun/2026